Home › Companies › ONCY
Oncolytics Biotech
Market cap $51.7M 136.1M shares (10-Q, Nov 13, 2026) × $0.380 close Nov 17, 2026
Most recent annual filing: 2026-03-30
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- REO 033 Part A interim2026REO 033 Part A interim, 2026, major
- Anal cancer pivotal start2H 2026Anal cancer pivotal start, 2H 2026, routine
- Pelareorep partnership2H 2026Pelareorep partnership, 2H 2026, routine
- Revolution Medicines RAS(ON) colorectal strategy4Q 2026Revolution Medicines RAS(ON) colorectal strategy, 4Q 2026, routine
- RAS-inhibitor combination preclinical readoutfall or winter of 2026RAS-inhibitor combination preclinical readout, fall or winter of 2026, notable
- REO 033 Part B trial1Q 2027REO 033 Part B trial, 1Q 2027, notable
- GOBLET Cohort 5 pancreatic interim1H 2027GOBLET Cohort 5 pancreatic interim, 1H 2027, notable
- SCAC/anal cancer study with Coherus1Q 2027SCAC/anal cancer study with Coherus, 1Q 2027, routine
- Common shares listing updateJan 19, 2027Common shares listing update, Jan 19, 2027, notable
- Zanzalintinib plus atezolizumab Exelixis PDUFAMar 3, 2027Zanzalintinib plus atezolizumab Exelixis PDUFA, Mar 3, 2027, material
- REO 033 toplineAug 30, 2027REO 033 topline, Aug 30, 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (4 active programs)
Discontinued (1)
- pelareorep — Pancreatic Ductal Adenocarcinoma · strategic deprioritization to focus on SCAC and CRC registrational programs; enrollment stopped at ~20 patients per arm
Capital (as filed)
- Cash
- $2.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$6.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $2.4M cash, runway about one month from September 30 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Oncolytics Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-17 Avoid Oncolytics Biotech (ONCY) - Scientific Deep Dive for Pelareorep and Pipeline Products Twenty-eight years of pharmacodynamic receipts have not produced a randomized benefit, the one randomized colorectal precedent was negative on PFS, and the trial is funded by an ATM drip at 77 cents with a reverse split and Nasdaq deadline looming — revisit only when REO 033 reports randomized Part A data with both arms' denominators and a partner funds Part B.
- 2026-10-28 Avoid UPDATE: Oncolytics Biotech (ONCY) - The Draft Footnote GOBLET final data restated DOR without a response rate or denominator, the anal cancer program remains unfunded with no partner, dilution per dollar raised has roughly doubled, and only randomized REO 033 Part A data with full denominators and outside funding for Part B would change the thesis.
- 2026-11-14 Avoid UPDATE: Oncolytics Biotech (ONCY) - A Month of Cash and a Borrowed PD-1 Q3 shows only $2.4M cash, ATM sales below 50 cents, a widening stockholders' deficit, a Nasdaq deadline of January 15, and REO 033 enrollment described in words suggesting a thin year-end dataset — the Coherus toripalimab supply deal addresses the right population but is not a partnership or registration-grade study.
- Avoid call · opened Sep 17, 2026 at $0.770 · -50.6% vs XBI -8.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer 4 Bennouna J. Lancet Oncol (14):29-37, 2023 21 During the second quarter of 2026, we continued with site initiation and expect that approximately half of the planned clinical sites will be activated during the third quarter of 2026.”
matched to REO 033 · topline data / matched to REO 033 Part B · trial initiation
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (45)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Sep 28, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC→ BD updateSummary on the 10-Q
- Nov 13, 202610-QQuarterly report→ BD updateOncolytics just named its first actual drug-supply partner for the anal cancer program — Coherus's toripalimab — while the Q3 10-Q reveals cash has fallen to $2.43M, the stockholders' deficit has widened to -$7.5M, and post-quarter ATM selling averaged just $0.47/share, all with the Nasdaq January 15 deadline now confirmed and the reverse split clock ticking louder.
- Nov 12, 20268-KCurrent report: other events · EX-99.1
- Nov 11, 2026ReleaseOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
- Nov 9, 2026ReleasePelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
- Nov 9, 20268-KCurrent report: other events · EX-99.1
- Nov 4, 2026ReleaseTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- Nov 4, 20268-KCurrent report: other events · EX-99.1
- Oct 27, 2026ReleaseOncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers→ BD updateSummary on the 8-K
- Oct 27, 20268-KCurrent report: other events · EX-99.1→ BD updateGOBLET Cohort 4's long-awaited final durability data just landed — ~15-month median DOR, all responders alive past 12 months — but the market isn't buying it, and a buried footnote reveals the efficacy figures come from "internal calculations for this draft," not a peer-reviewed dataset.
- Oct 20, 2026ReleaseOncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
- Oct 20, 20268-KCurrent report: other events · EX-99.1
- Oct 14, 2026ReleaseOncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
- Oct 14, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ONCY pipeline
- Oct 13, 20268-KCurrent report: other events · EX-99.1
- Oct 12, 2026ReleaseOncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
- Oct 6, 2026DEFA14AProxy soliciting material
- Oct 6, 2026DEF 14AProxy statement
- Sep 29, 2026ReleaseOncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
- Sep 29, 20268-KCurrent report: other events · EX-99.1
- Sep 28, 2026ReleaseOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
- Sep 28, 20268-KCurrent report: other events · EX-99.1
- Sep 10, 20268-KCurrent report: other events · EX-99.1
- Aug 18, 20268-KCurrent report: other events · EX-99.1
- Aug 12, 202610-QQuarterly report
- Jul 24, 20268-KCurrent report: listing notice
- Jul 20, 20268-KCurrent report: other events · EX-99.1
- Jul 13, 20268-KCurrent report: other events · EX-99.1
- Jul 8, 20268-KCurrent report: auditor change
- Jun 16, 20268-KCurrent report: other events · EX-99.1
- Jun 2, 20268-KCurrent report: officer / director change, other events · EX-99.1
- Jun 1, 20268-KCurrent report: other events · EX-99.1
- May 22, 20268-KCurrent report: other events · EX-99.1
- May 14, 202610-QQuarterly report
- May 4, 20268-KCurrent report: other events · EX-99.1
- Apr 27, 20268-KCurrent report: other events · EX-99.1
- Apr 6, 20268-KCurrent report: other events · EX-99.1
- Apr 6, 20268-KCurrent report: other events
- Apr 6, 2026424B5Prospectus supplement (offering)
- Apr 1, 2026S-3Shelf registration
- Apr 1, 20268-KCurrent report: material agreement, holder rights modified, officer / director change · EX-99.2 EXHIBIT 99.2
- Mar 30, 202610-KAnnual report
- Mar 20, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year
- Mar 19, 20268-KCurrent report: other events · EX-99.1
- Mar 2, 20268-KCurrent report: other events · EX-99.1
48 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026F-10POSF-10POS
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 8, 2026AWAW
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 6, 2026F-10POSF-10POS
- Apr 3, 2026EFFECTRegistration effective
- Apr 1, 2026UPLOADUPLOAD
- Apr 1, 2026S-8 POSEmployee plan registration (post-effective)
- Apr 1, 2026S-8 POSEmployee plan registration (post-effective)
- Apr 1, 2026S-8Employee plan registration
- Apr 1, 2026POS AMPost-effective amendment
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026F-10POSF-10POS
- Apr 1, 2026EFFECTRegistration effective
- Apr 1, 2026CORRESPCORRESP